While intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs have greatly improved the visual outcome of wet AMD (Brynskov et al., 2020), there is no treatment for dry AMD, which affects most patients. Here, VEGFA is linked to dry age related macular degeneration.